Phase 3 N=37 Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
Multiple Sclerosis
Primary: Time-to-exhaustion — 551.7; 331.6; 578.2 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=490 A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Colo-rectal Cancer
Primary: Overall Response Rate — 2; 5; 116; 116 Participants
Phase 3 N=60 A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
Anesthesia, Local
Primary: The Proportion of Participants in Which an Eye Exam Was Able to be Performed — 30; 30 Participants
Phase 3 N=140 MabionCD20 Compared to MabThera in Lymphoma Patients
Diffuse Large B-Cell Lymphoma
Primary: Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) — 1559.51; 1509.79 (μg*day)/mL
Phase 3 N=10 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma
Primary: Number of Participants With Dose-limiting Toxicity (DLT) [Lead-in Phase] — 0 Participants
Phase 3 N=1,537 Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo…
Phase 3 N=43 Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 3.73; 4.28; 6.31; 5.24 bleeding events per year
Phase 3 N=519 Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
Colonoscopy
Primary: Proportion of Subjects With Successful Bowel Preparation — 215; 212 Participants — p=<0.001
Phase 3 N=244 A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
Parkinson's Disease (PD)
Primary: Number of Participants With Adverse Events — 121; 109; 230; 32 Participants
Phase 3 N=260 A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
Dry Eye
Primary: Change From Baseline in Central Corneal Staining Score (CCSS) at Day 57 — 2.40; 2.37; -0.82; -0.79 score on a scale — p=0.764
Phase 3 N=919 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)…
Phase 3 N=396 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Crohn's Disease
Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001
Phase 3 N=44 Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Primary Immunodeficiency Diseases (PID)
Primary: Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year — 0.04 ASBI per participant-year
Phase 3 N=437 SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival — 7.0; 4.9 months — p==0.002
Phase 3 N=475 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
COVID-19 · Lung Infection
Primary: Supplemental Oxygen Requirement — 139; 132; 91; 101 Participants — p=0.391